ES2184762T3 - Allquil bencilaminoquinuclidinas sustituidas con heteroatomos como antagonista de la sustancia p'. - Google Patents

Allquil bencilaminoquinuclidinas sustituidas con heteroatomos como antagonista de la sustancia p'.

Info

Publication number
ES2184762T3
ES2184762T3 ES94914619T ES94914619T ES2184762T3 ES 2184762 T3 ES2184762 T3 ES 2184762T3 ES 94914619 T ES94914619 T ES 94914619T ES 94914619 T ES94914619 T ES 94914619T ES 2184762 T3 ES2184762 T3 ES 2184762T3
Authority
ES
Spain
Prior art keywords
sub
sup
rent
replaced
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94914619T
Other languages
English (en)
Inventor
Kunio Satake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PFIZER
Pfizer Inc
Original Assignee
PFIZER
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PFIZER, Pfizer Inc filed Critical PFIZER
Application granted granted Critical
Publication of ES2184762T3 publication Critical patent/ES2184762T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE PRESENTAN COMPUESTOS UTILES EN EL TRATAMIENTO DE ENFERMEDADES INFLAMATORIAS, ENFERMEDADES DEL SISTEMA NERVIOSO CENTRAL Y OTRAS ENFERMEDADES, DE LA FORMULA (I) ASI COMO LAS SALES FARMACOLOGICAMENTE ACEPTABLES DE LOS MISMOS; EN DONDE R ES ALQUILO C{SUB, 1-6}; X ES ALQUILO C{SUB, 1-6} QUE TIENE UNO O MAS SUSTITUYENTES QUE INCLUYEN AL MENOS UN HETEROATOMO; AR{SUP, 1} Y AR{SUP, 2} SON CADA UNA INDEPENDIENTEMENTE ARILO OPCIONALMENTE SUSTITUIDO POR UNO O MAS ALQUILO C{SUB, 1-6}, ALQUILTIO C{SUB, 1-6}, HALOGENO, CIANO, NITRO, FENOXIDO, MONOALQUILAMINO C{SUB, 1-6}, DIALQUILAMINO C{SUB, 1-6}, ALQUIL C{SUB, 1-6} HALOSUSTITUIDO, O ALCOXIDO C{SUB, 1-6} HALOSUSTITUIDO; Y ES HIDROGENO, ALQUIL C{SUB, 1-6} ALQUENIL C{SUB, 2-6}, CICLOALQUIL C{SUB, 3-8}, Z-(CH{SUB, 2}{SUB, P-}, O W-(CH{SUB, 2}){SUB, M}CHR{SUP, 2}(CH{SUB, 2}{SUB, N}-NR{SUP, 1}CO- EN DONDE Y ESTA SUSTITUIDA EN LA POSICION 4-, 5- O 6- EN UN ANILLO DE QUINUCLIDINA; R{SUP, 1} ES HIDROGENO, ALQUIL C{SUB, 1-6}, BENCIL O -(CH{SUB, 2}{SUB, R}-W; R{SUB, 2} ES HIDROGENO O ALQUIL C{SUB, 1-6} QUE PUEDE SER SUSTITUIDA POR UN HIDROXIDO, AMINO, METILTIO, METILMERCAPTO, BENCILO, 4-HIDROXIBENCILO, 3-INDOLILMETILO O (CH{SUB, 2}{SUB, R}; R{SUB, 1} PUEDE FORMAR UN ANILLO CON R{SUB, 2}; Z ES ALCOXIDO C{1-6}, -CONR{SUP, 4}R{SUP, 5}, -CO{SUB, 2}R{SUP, 4}, -CHR{SUP, 4}OR{SUP, 5}, -CHR{SUP, 4}NR{SUP, 5}R{SUP, 6}, -COR{SUP, 4}, -CONR{SUP, 4}OR{SUP, 5} O OPCIONALMENTE SUSTITUIDO POR ARIL; CADA W ES INDEPENDIENTEMENTE CIANO, HIDROXIMETILO, ALCOXIMETILO C{SUB, 2-6}, AMINOMETILO, MONOALQUILAMINOMETILO C{SUB, 1-6}, DIALQUILAMINOMETILO C{SUB, 16}, CARBOXILO, CARBAMOILO O ALCOXICARBONILO C{SUB, 1-6}; R{SUP, 4}, R{SUP, 5} Y R{SUP, 6} SON INDEPENDIENTEMENTE HIDROGENO, ALQUIL C{SUB, 1-6}, ALCOXIDO C{SUB, 1-6}, CICLOALQUILO C{SUB, 38} U OPCIONALMENTE ARIL SUSTITUIDO O UN GRUPO HETEROCICLICO; P ES 0-6; Y M, N Y R SON CADA UNA INDEPENDIENTEMENTE, 0-3.
ES94914619T 1993-05-19 1994-05-13 Allquil bencilaminoquinuclidinas sustituidas con heteroatomos como antagonista de la sustancia p'. Expired - Lifetime ES2184762T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11710293 1993-05-19

Publications (1)

Publication Number Publication Date
ES2184762T3 true ES2184762T3 (es) 2003-04-16

Family

ID=14703456

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94914619T Expired - Lifetime ES2184762T3 (es) 1993-05-19 1994-05-13 Allquil bencilaminoquinuclidinas sustituidas con heteroatomos como antagonista de la sustancia p'.

Country Status (12)

Country Link
US (1) US5741797A (es)
EP (1) EP0699199B1 (es)
AT (1) ATE228129T1 (es)
AU (1) AU6691094A (es)
CA (1) CA2161886C (es)
DE (1) DE69431751T2 (es)
DK (1) DK0699199T3 (es)
ES (1) ES2184762T3 (es)
FI (1) FI942314A7 (es)
IL (1) IL109646A0 (es)
PT (1) PT699199E (es)
WO (1) WO1994026740A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10508837A (ja) * 1994-11-10 1998-09-02 ファイザー・インコーポレーテッド 眼の疾患を治療するためのｎｋ−１レセプターアンタゴニスト
DE69623580T2 (de) 1995-12-21 2003-01-09 Pfizer Inc., New York 3-((5-Substituierte Benzyl)Amino)-2-Phenylpiperidine als Substance-P-Antagonisten
MX9706944A (es) * 1996-09-12 1998-08-30 Pfizer Quinuclidinas sustituidas con tetrazolilo como antagonistas de la sustancia p.
WO2001032625A1 (en) 1999-11-03 2001-05-10 Du Pont Pharmaceuticals Company Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
JP5132864B2 (ja) 2000-07-11 2013-01-30 アルバニー モレキュラー リサーチ， インコーポレイテッド ４−フェニル置換テトラヒドロイソキノリンおよびその使用方法
KR20040029375A (ko) * 2001-07-20 2004-04-06 화이자 프로덕츠 인코포레이티드 개, 고양이 및 말에서 결함있는 행태를 변화시키기 위한ｎｋ-1 수용체 길항제의 용도
US20060205724A1 (en) * 2002-05-29 2006-09-14 The Regents Of The University Of California Antagonizing nk-1 receptors inhibits consumption of substances of abuse
US6861526B2 (en) 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
AU2005274927B2 (en) 2004-07-15 2011-11-03 Albany Molecular Research, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
KR101594898B1 (ko) 2005-07-15 2016-02-18 알바니 몰레큘라 리써치, 인크. 아릴- 및 헤테로아릴-치환된 테트라히드로벤자제핀, 및 노르에피네프린, 도파민 및 세로토닌의 재흡수를 차단하기 위한 용도
KR20080048502A (ko) 2005-09-29 2008-06-02 머크 앤드 캄파니 인코포레이티드 멜라노코르틴-4 수용체 조절제로서의 아실화스피로피페리딘 유도체
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
US20070238630A1 (en) * 2006-03-29 2007-10-11 Phillips Douglas H Subcutaneous skin cleanser
US8173629B2 (en) 2006-09-22 2012-05-08 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
EA016079B1 (ru) 2007-01-10 2012-01-30 Институто Ди Ричерке Ди Биолоджиа Молеколаре П. Анджелетти Спа Амидзамещенные индазолы в качестве ингибиторов поли(adp-рибоза)полимеразы (parp)
JP5319518B2 (ja) 2007-04-02 2013-10-16 Ｍｓｄ株式会社 インドールジオン誘導体
AU2008269154B2 (en) 2007-06-27 2014-06-12 Merck Sharp & Dohme Llc 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CN102014631A (zh) 2008-03-03 2011-04-13 泰格尔医药科技公司 酪氨酸激酶抑制剂
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
WO2010114780A1 (en) 2009-04-01 2010-10-07 Merck Sharp & Dohme Corp. Inhibitors of akt activity
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
CN102458123A (zh) 2009-05-12 2012-05-16 阿尔巴尼分子研究公司 芳基、杂芳基和杂环取代的四氢异喹啉及其用途
US8802696B2 (en) 2009-05-12 2014-08-12 Albany Molecular Research, Inc. 7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoqu inoli and use thereof
JP5099731B1 (ja) 2009-10-14 2012-12-19 メルク・シャープ・アンド・ドーム・コーポレーション ｐ５３活性を増大する置換ピペリジン及びその使用
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
AU2011285909B2 (en) 2010-08-02 2016-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (en) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF HEPATITIS B VIRUS (HBV) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
EP3766975A1 (en) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
EP2699567A1 (en) 2011-04-21 2014-02-26 Merck Sharp & Dohme Corp. Insulin-like growth factor-1 receptor inhibitors
WO2013063214A1 (en) 2011-10-27 2013-05-02 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP3358013B1 (en) 2012-05-02 2020-06-24 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
KR20150060724A (ko) 2012-09-28 2015-06-03 머크 샤프 앤드 돔 코포레이션 Erk 억제제인 신규 화합물
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
DK2925888T3 (en) 2012-11-28 2017-12-18 Merck Sharp & Dohme COMPOSITIONS AND METHODS OF CANCER TREATMENT
EP2935263B1 (en) 2012-12-20 2018-12-05 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2018071283A1 (en) 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
US11098059B2 (en) 2017-11-08 2021-08-24 Merck Sharp & Dohme Corp. PRMT5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
BR112021002267A8 (pt) 2018-08-07 2023-02-07 Merck Sharp & Dohme Inibidores de prmt5
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
PL172069B1 (pl) * 1991-05-22 1997-07-31 Pfizer Sposób wytwarzania nowych pochodnych podstawionej 3-aminochinuklidyny PL PL PL PL PL
CA2102179C (en) * 1991-05-31 1998-10-27 Fumitaka Ito Quinuclidine derivatives
HU224443B1 (hu) * 1991-06-20 2005-09-28 Pfizer Inc. Fluor-alkoxi-benzaldehid-származékok
JP2656702B2 (ja) * 1992-03-23 1997-09-24 ファイザー製薬株式会社 ペプチド性キヌクリジン
JP2656700B2 (ja) * 1992-10-28 1997-09-24 ファイザー製薬株式会社 置換キヌクリジン誘導体
US5294744A (en) * 1993-04-20 1994-03-15 Pfizer Inc. Formylation process for aromatic aldehydes
JP3326489B2 (ja) * 1996-02-10 2002-09-24 好高 青山 部品供給ロッド装置とそれによる供給方法
JPH09221677A (ja) * 1996-02-14 1997-08-26 Kansai Coke & Chem Co Ltd 石炭の高温予熱方法
JPH09319064A (ja) * 1996-05-29 1997-12-12 Konica Corp 写真製品の生産方法及び生産装置

Also Published As

Publication number Publication date
FI942314A0 (fi) 1994-05-18
EP0699199B1 (en) 2002-11-20
DE69431751T2 (de) 2003-04-03
WO1994026740A1 (en) 1994-11-24
CA2161886A1 (en) 1994-11-24
PT699199E (pt) 2003-01-31
FI942314L (fi) 1994-11-20
FI942314A7 (fi) 1994-11-20
CA2161886C (en) 1999-12-07
ATE228129T1 (de) 2002-12-15
DE69431751D1 (de) 2003-01-02
US5741797A (en) 1998-04-21
AU6691094A (en) 1994-12-12
DK0699199T3 (da) 2002-12-16
EP0699199A1 (en) 1996-03-06
IL109646A0 (en) 1994-08-26

Similar Documents

Publication Publication Date Title
MX9301634A (es) Quinuclidinas peptidicas.
ES2132223T3 (es) Derivados de indol condensados en calidad de antagonistas del receptor 5-ht4.
ES2127946T3 (es) Antagonistas de neurocinina diazabiciclica.
ES2113368T3 (es) Antagonistas de serotonina.
ES2165505T3 (es) Compuestos aromaticos y composiciones farmaceuticas que los contienen.
ES2062374T3 (es) Heteroarilpiperazinas, agentes antipsicoticos.
ES2184797T3 (es) Uso de antagonistas de serotonina (5ht3) para el tratamiento de la fibromialgia.
ES2157353T3 (es) Oximas de la rapamicina en posicion 42 e hidroxilaminas.
ES2040838T3 (es) Compuestos piperazinil-heterociclicos.
ES2065691T3 (es) Derivados de quinuclidina.
ES2052675T3 (es) 3-(4-piperazinil-sustituido en 1)butil)-4-tiazolidinonas, un procedimiento para su preparacion y su uso como medicamentos.
PT86980A (pt) Process for preparing benzodiazepine analogs
ES2083569T3 (es) Nuevos derivados de ariletenileno y procedimiento para su preparacion.
ES2148476T3 (es) Derivados de azabicicloalcano n-substituidos como neurolepticos asf.
ES2096560T3 (es) Compuestos de benzocicloheptapiridina sustituida con fluor, composiciones y metodos para uso como compuestos antihistaminicos.
ES2054627T3 (es) Indolinas 3,3-disustituidas.
ES2184794T3 (es) Profarmacos de morfolina como antagonistas de receptores de taquicininas.
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
ES2158840T3 (es) Nuevos analogos de adenosina carbociclicos utiles como inmunosupresores.
ES2167544T3 (es) Dioxidos de benzotiazina como antagonistas de la endotelina.
ES2164366T3 (es) Derivados de la distamicina acriloil sustituidos, procedimiento de fabricacion asociado y su utilizacion como agentes antitumorales y antivirales.
ES2155827T3 (es) 4-carboxiimidazoles como antagonistas de la angiotensina ii y su uso terapeutico.
ES2079570T3 (es) Nuevas pirido(2,3-f)(1,4)tiazepinas y pirido(3,2-b)(1,5)benzotiazepinas.
ES2152682T3 (es) Derivados de indolina utiles como antagonistas del receptor 5ht-2c.
ES2196069T3 (es) Derivados morfinoides condensados con heterociclos.